Intec Pharma Ltd. (NASDAQ:NTEC) has received an average recommendation of “Buy” from the six research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $11.00.

Several brokerages have weighed in on NTEC. Oppenheimer boosted their price objective on Intec Pharma from $10.00 to $15.00 and gave the company an “outperform” rating in a research report on Thursday, September 21st. Roth Capital set a $10.00 price objective on Intec Pharma and gave the company a “buy” rating in a research report on Thursday, August 10th. Zacks Investment Research upgraded Intec Pharma from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd. CIBC reiterated an “outperform” rating and issued a $15.00 price objective (up previously from $10.00) on shares of Intec Pharma in a research report on Thursday, September 21st. Finally, Maxim Group set a $8.00 target price on Intec Pharma and gave the company a “buy” rating in a report on Friday, November 17th.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Caxton Corp purchased a new stake in shares of Intec Pharma in the third quarter worth $681,000. Pura Vida Investments LLC purchased a new stake in shares of Intec Pharma in the third quarter worth $895,000. Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of Intec Pharma by 5.0% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 522,200 shares of the biotechnology company’s stock worth $2,977,000 after acquiring an additional 25,000 shares during the last quarter. Finally, Sectoral Asset Management Inc purchased a new stake in shares of Intec Pharma in the third quarter worth $3,177,000. 40.16% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Intec Pharma (NASDAQ NTEC) traded up $0.05 during mid-day trading on Tuesday, reaching $5.35. The company’s stock had a trading volume of 32,801 shares, compared to its average volume of 45,326. Intec Pharma has a 12-month low of $4.20 and a 12-month high of $9.80.

COPYRIGHT VIOLATION WARNING: “Analysts Set Intec Pharma Ltd. (NTEC) PT at $11.00” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/12/08/analysts-set-intec-pharma-ltd-ntec-pt-at-11-00.html.

About Intec Pharma

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Receive News & Ratings for Intec Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.